Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer

Prasad R. Dandawate; Alok Vyas; Aamir Ahmad; Sanjeev Banerjee; Jyoti Deshpande; K. Venkateswara Swamy; Abeda Jamadar; Subhash Padhye; Fazlul H. Sarkar; Anne Duhme-Klair

doi:10.1007/s11095-012-0700-1

Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer

Prasad R. Dandawate, Alok Vyas, Aamir Ahmad, Sanjeev Banerjee, Jyoti Deshpande, K. Venkateswara Swamy, Abeda Jamadar, Subhash Padhye, Fazlul H. Sarkar, Anne Duhme-Klair

Chemistry

Research output: Contribution to journal › Article › peer-review

Abstract

Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-beta-cyclodextrin inclusion complex (1:2) (CDFCD).

The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked.

CDF-beta-cyclodextrin was found to lower IC50 value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-beta-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-beta-cyclodextrin preparation.

Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-beta-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.

Original language	English
Pages (from-to)	1775-1786
Number of pages	12
Journal	Pharmaceutical research
Volume	29
Issue number	7
DOIs	https://doi.org/10.1007/s11095-012-0700-1
Publication status	Published - Jul 2012

Access to Document

10.1007/s11095-012-0700-1

Cite this

Dandawate, P. R., Vyas, A., Ahmad, A., Banerjee, S., Deshpande, J., Swamy, K. V., Jamadar, A., Padhye, S., Sarkar, F. H., & Duhme-Klair, A. (2012). Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer. Pharmaceutical research, 29(7), 1775-1786. https://doi.org/10.1007/s11095-012-0700-1

@article{76579849c137450e858d631070cb9c03,

title = "Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer",

abstract = "Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-beta-cyclodextrin inclusion complex (1:2) (CDFCD).The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked.CDF-beta-cyclodextrin was found to lower IC50 value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-beta-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-beta-cyclodextrin preparation.Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-beta-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.",

author = "Dandawate, {Prasad R.} and Alok Vyas and Aamir Ahmad and Sanjeev Banerjee and Jyoti Deshpande and Swamy, {K. Venkateswara} and Abeda Jamadar and Subhash Padhye and Sarkar, {Fazlul H.} and Anne Duhme-Klair",

year = "2012",

month = jul,

doi = "10.1007/s11095-012-0700-1",

language = "English",

volume = "29",

pages = "1775--1786",

journal = "Pharmaceutical research",

issn = "0724-8741",

publisher = "Springer",

number = "7",

}

Dandawate, PR, Vyas, A, Ahmad, A, Banerjee, S, Deshpande, J, Swamy, KV, Jamadar, A, Padhye, S, Sarkar, FH & Duhme-Klair, A 2012, 'Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer', Pharmaceutical research, vol. 29, no. 7, pp. 1775-1786. https://doi.org/10.1007/s11095-012-0700-1

TY - JOUR

T1 - Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer

AU - Dandawate, Prasad R.

AU - Vyas, Alok

AU - Ahmad, Aamir

AU - Banerjee, Sanjeev

AU - Deshpande, Jyoti

AU - Swamy, K. Venkateswara

AU - Jamadar, Abeda

AU - Padhye, Subhash

AU - Sarkar, Fazlul H.

AU - Duhme-Klair, Anne

PY - 2012/7

Y1 - 2012/7

N2 - Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-beta-cyclodextrin inclusion complex (1:2) (CDFCD).The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked.CDF-beta-cyclodextrin was found to lower IC50 value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-beta-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-beta-cyclodextrin preparation.Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-beta-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.

AB - Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-beta-cyclodextrin inclusion complex (1:2) (CDFCD).The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked.CDF-beta-cyclodextrin was found to lower IC50 value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-beta-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-beta-cyclodextrin preparation.Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-beta-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.

U2 - 10.1007/s11095-012-0700-1

DO - 10.1007/s11095-012-0700-1

M3 - Article

SN - 0724-8741

VL - 29

SP - 1775

EP - 1786

JO - Pharmaceutical research

JF - Pharmaceutical research

IS - 7

ER -